JACC This Week · American College of Cardiology

Heart Failure in Practice: Dual Therapy Insights, Digital Innovation & the Future of Risk Models | JACC This Week

·12 min·1 clip

The Salgaldi-PEF trial shows dual therapy reduces NT-proBNP by 11% but causes a nearly 10 mL/min eGFR decline.

This episode of JACC This Week reviews recent research on heart failure, covering dual therapy insights from the Salgaldi-PEF trial, risks of therapy withdrawal in improved ejection fraction patients, finerenone discontinuation effects, sex differences in genetic cardiomyopathy, and updates on ICD use and digital tools.

Listen to the show on

Apple Podcasts Spotify

Play clips from this episode More from JACC This Week